| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 174: 23-30 (1999)
© 1999 The Royal College of Psychiatrists
CM Beasley, MA Dellva, RN Tamura, H Morgenstern, WM Glazer, K Ferguson and GD Tollefson
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
BACKGROUND: Tardive dyskinesia is important in the side-effect profile of antipsychotic medication. AIMS: The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years. METHODS: Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD), it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated. RESULTS: The relative risk of tardive dyskinesia for the overall follow up period for haloperidol (n = 522) v. olanzapine (n = 1192) was 2.66 (95% CI = 1.50-4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n = 513) and 7.45% with haloperidol (n = 114). The relative risk throughout this follow-up period was 11.37 (95% CI = 2.21-58.60). CONCLUSION: Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.
This article has been cited by other articles:
|
|
 |
|
  R. A. Rosenheck Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics The British Journal of Psychiatry, September 1, 2007; 191(3): 238 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
 |
|
 J. M. Noel ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876. [Full Text] [PDF]
|
|
|
|
|
|
G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. McGLASHAN Early detection and intervention in psychosis: an ethical paradigm shift The British Journal of Psychiatry, August 1, 2005; 187(48): s113 - s115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Gardner, R. J. Baldessarini, and P. Waraich Modern antipsychotic drugs: a critical overview Can. Med. Assoc. J., June 21, 2005; 172(13): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rosenheck Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator Psychiatr Serv, January 1, 2005; 56(1): 85 - 92. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Keith, L. Pani, B. Nick, R. Emsley, L. San, M. Turner, R. Conley, P. Scully, P. S. Chue, and B. Lachaux Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia Psychiatr Serv, September 1, 2004; 55(9): 997 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Glazer Olanzapine vs Haloperidol for Treatment of Schizophrenia JAMA, March 3, 2004; 291(9): 1064 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
R. Rosenheck, D. Perlick, S. Bingham, and J. Collins Olanzapine vs Haloperidol for Treatment of Schizophrenia--Reply JAMA, March 3, 2004; 291(9): 1065 - 1066. [Full Text] [PDF]
|
|
|
|
 |
|
 C. U. Correll, S. Leucht, and J. M. Kane Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Am J Psychiatry, March 1, 2004; 161(3): 414 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Jibson, I. D. Glick, and R. Tandon Schizophrenia and Other Psychotic Disorders Focus, January 1, 2004; 2(1): 17 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Bella and F. Piccoli Olanzepine-induced tardive dyskinesia The British Journal of Psychiatry, January 2, 2003; 182 (1): 81 - 82. [Full Text] [PDF]
|
|
|
|
|
|
R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) Focus, January 1, 2003; 1(1): 64 - 110. [Full Text] [PDF]
|
|
|
|
 |
|
 G D Honey, P C Fletcher, and E T Bullmore Functional brain mapping of psychopathology J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 432 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shamir, Y. Barak, I. Shalman, M. Laudon, N. Zisapel, R. Tarrasch, A. Elizur, and R. Weizman Melatonin Treatment for Tardive Dyskinesia: A Double-blind, Placebo-Controlled, Crossover Study Arch Gen Psychiatry, November 1, 2001; 58(11): 1049 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Einfeld Systematic management approach to pharmacotherapy for people with learning disabilities Advan. Psychiatr. Treat., January 1, 2001; 7(1): 43 - 49. [Full Text]
|
|
|
|
 |
|
 J. Meara and P. Hobson Review: tardive dyskinesia is a risk factor for mortality in psychiatric patients Evid. Based Ment. Health, November 1, 2000; 3(4): 123 - 123. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
